TEVA B1 (Letrozole 2.5 mg)

Pill with imprint TEVA B1 is Yellow, Round and has been identified as Letrozole 2.5 mg. It is supplied by Teva Pharmaceuticals USA Inc.

Letrozole is used in the treatment of breast cancer, metastatic; breast cancer, adjuvant; breast cancer and belongs to the drug classes aromatase inhibitors, hormones/antineoplastics. There is positive evidence of human fetal risk during pregnancy. Letrozole 2.5 mg is not a controlled substance under the Controlled Substances Act (CSA).

Images for TEVA B1

Letrozole

Imprint

TEVA B1

Strength

2.5 mg

Color

Yellow

Size

6.00 mm

Shape

Round

Availability

Prescription only

Drug Class

Aromatase inhibitors, Hormones/antineoplastics

Pregnancy Category

D - Positive evidence of risk

CSA Schedule

Not a controlled drug

Labeler / Supplier

Teva Pharmaceuticals USA Inc

Inactive Ingredients

silicon dioxide, FD&C Blue No. 2, indigotindisulfonate sodium, FD&C Yellow No. 5, ferric oxide yellow, lactose monohydrate, magnesium stearate, microcrystalline cellulose, polyethylene glycol 3350, polyethylene glycol 4000, sodium starch glycolate type A potato, corn starch, magnesium silicate, titanium dioxide

Note: Inactive ingredients may vary.

Labelers / Repackagers

NDC Code	Labeler / Repackager
00093-7620	Teva Pharmaceuticals USA, Inc.
42291-0374	AvKare, Inc.

More Info Imprint Search Print

Get help with Imprint Code FAQs.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer